BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

Submitted by Anonymous on

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus Key Takeaways BDTX is advancing silevertinib into glioblastoma, broadening its CNS-focused opportunity set.A randomized phase II GBM study began in May 2026, with...

Dizal's ZEGFROVY (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

Submitted by Anonymous on

上海，2026年5月27日/美通社/ --...

Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

Submitted by Anonymous on

SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has...

The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic Analysis

Submitted by Anonymous on

AbstractBackground Epidermal growth factor receptor-mutated (EGFR-M+) non-small-cell lung cancer (NSCLC) represents a substantial proportion of lung cancer and remains associated with a considerable risk of postoperative recurrence despite advances in targeted therapies. The role of programmed death-ligand 1 (PD-L1) expression...

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

Submitted by Anonymous on

BackgroundHepatic metastasis and uncommon mutations are recognized risk factors in patients with epidermal growth factor receptor (EGFR)-mutant non–small cel Abstract Background: Hepatic metastasis and uncommon mutations are recognized risk factors in patients with epidermal growth factor receptor (EGFR)-mutant non–small cell...

Tyrosine phosphatase SHP2 accelerated progression of thymic epithelial tumors via promoting PI3K/ERK/CREB/SP1 induced HIF1α and EGFR expression

Submitted by Anonymous on

AbstractObjective To investigate the impact of SHP2 on thymic epithelial tumors (TETs) and its underlying mechanisms. Methods Bioinformatic analysis was performed to identify key pathways in TETs. Clinical samples from 40 TET patients and 3 normal controls were analyzed. Immunohistochemistry...

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

Submitted by Anonymous on

BackgroundIvonescimab, a novel PD-1/VEGF bispecific antibody, has shown promising efficacy in advanced lung cancer. Yet severe immune-related adverse events Abstract Background: Ivonescimab, a novel PD-1/VEGF bispecific antibody, has shown promising efficacy in advanced lung cancer. Yet severe immune-related adverse events...

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression

Submitted by Anonymous on

Abstract Immune checkpoint blockade has revolutionized the treatment of lung cancer; however, therapeutic responses remain heterogeneous, particularly in patients harboring activating epidermal growth factor receptor (EGFR) mutations. Emerging evidence identifies human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), a...

Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy

Submitted by Anonymous on

Third-generation tyrosine kinase inhibitors (TKIs) have become the standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. Currently, after developing resistance to third-generation EGFR-TKIs, treatment regimens based on platinum-based dual-agent chemotherapy yield limited clinical benefit. This retrospective study...

Subscribe to Newsfeed